Clinical study of ticrynafen. A new diuretic, antihypertensive, and uricosuric agent.
In a double-blind study, 20 hypertensive patients were randomly assigned to a six-week regimen of either ticrynafen or hydrochlorothiazide. Blood pressure was significantly reduced with both medications, although most patients required an increase in dosage from 250 to 500 mg ticrynafen daily. Whereas the serum uric acid level rose moderately in the hydrochlorothiazide-treated patients, it fell strikingly to less than half of the pretreatment level in patients treated with ticryafen. Body weight decreased slightly in both groups, as did serum potassium levels. Blood urea nitrogen and serum creatinine levels rose slightly in both groups. The magnitude of these changes was not significantly different between the two groups. Use of ticryafen was well tolerated. Ticryafen appears to be a useful new antihypertensive agent because of its unique combination of diuretic, antihypertensive, and hypouricemic effects.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D004232:Diuretics; D004341:Drug Evaluation; D006016:Glycolates / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006852:Hydrochlorothiazide / Q000494:pharmacology / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010642:Phenoxyacetates / Q000494:pharmacology / Q000627:therapeutic use*; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood; D014528:Uricosuric Agents
D000959:Antihypertensive Agents; D004232:Diuretics; D006016:Glycolates; D010642:Phenoxyacetates; D013876:Thiophenes; D014528:Uricosuric Agents; D006852:Hydrochlorothiazide; D014527:Uric Acid